- Home
- GLOB vs PRCT Comparison
GLOB vs PRCT Comparison
Compare GLOB & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLOB | PRCT |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLOB | PRCT |
|---|---|---|
| Price | $37.50 | $20.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $71.60 | $35.44 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $2.98 | $31.34 |
| Revenue Next Year | $5.18 | $24.52 |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $27.56 | $16.67 |
| 52 Week High | $79.66 | $42.71 |
Technical Indicators
Market Signals| Indicator | GLOB | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.17 | 52.75 |
| Support Level | $28.40 | $19.64 |
| Resistance Level | $38.97 | $29.27 |
| Average True Range (ATR) | 2.12 | 1.15 |
| MACD | 0.69 | 0.39 |
| Stochastic Oscillator | 82.29 | 99.12 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.